Results 11 to 20 of about 21,646 (232)
Pharmacokinetics and Pharmacogenetics of Dabigatran
Рациональная фармакотерапия в кардиологии, 2021 Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin. Pharmacokinetics of dabigatran etexilate doesn’t have the disadvantages of vitamin K antagonists.
A. V. Savinova +4 more
doaj +4 more sources
Thrombocytopenia induced by dabigatran: two case reports
BMC Neurology, 2017 Background Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke).
Hyun Goo Kang +3 more
doaj +2 more sources
Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia
Life, 2022 Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair +5 more
doaj +2 more sources
Patient Preference and Adherence, 2014 Jiyoon C Choi,1 Marco d DiBonaventura,2 Lewis Kopenhafer,2 Winnie W Nelson31LifeScan, Inc, West Chester, PA, 2Health Sciences Practice, Kantar Health, New York, NY, 3Janssen Scientific Affairs LLC, Raritan, NJ, USABackground: Oral dabigatran was recently
Choi JC +3 more
doaj +1 more source
Vascular Health and Risk Management, 2013 Andreas Clemens,1 Mandy Fraessdorf,2 Jeffrey Friedman31Corporate Division Medicine, TA Cardiovascular, 2Medical Data Services, Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany; 3Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT ...
Clemens A, Fraessdorf M, Friedman J
doaj +1 more source
The new way of Dabigatran reversal – Idarucizumab
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +5 more sources
American Journal of Neuroradiology, 2011 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
L, Murphy, L, Lawler, E C, Kavanagh
+6 more sources
Cells, 2021 Dabigatran is a novel oral anticoagulant that directly inhibits free and fibrin-bound thrombins and exerts rapid and predictable anticoagulant effects. While the use of this reagent has been associated with an increased risk of gastrointestinal bleeding,
Hiromi Kurokawa +3 more
doaj +1 more source
Pharmaceuticals, 2023 Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung +5 more
doaj +1 more source
Dabigatran: Clinical correlation of drug and its dose with risk of stroke and bleeding
Perspectives in Clinical Research, 2023 Background: Dabigatran is the first oral direct thrombin inhibitor which is endorsed by Food and Drug Administration in the prevention of embolic events in patients with nonvalvular atrial fibrillation.
Anitta Shaji +4 more
doaj +1 more source